ABBV

AbbVie Inc. NYQ · ABBV

$254.49 +0.10 (+0.04%)

Extended · +1.46σ

+ Compare Open in Sniper

Mkt cap $449.6B

P/E 124.8

Day $254.29 – $260.96

52wk $190.75 – $261.64

Avg vol 7.1M

Beta 0.28

Div yld 2.72%

Next earnings 2026-07-31

Quick read

Plain English

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

ABBV last traded at $254.49, up 0.0% on the day; that's in the upper part of its 52-week range ($190.75–$261.64). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

The next scheduled earnings report (2026-07-31) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC2 upper, +1.42 ATR from EMA21 — no notable pattern

Long —

score 19 · tech 19 / 80 · support 0 / 20

above KC1 lower, +1.42 ATR from EMA21 · no notable pattern

· Stochastic bull cross
· Aligned with strong uptrend (strong tailwind)

How this grade was earned

total 19 pts

Cycle position 6

Momentum 3

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 22 · tech 22 / 80 · support 0 / 20

KC2 upper, +1.42 ATR from EMA21 · no notable pattern

ℹ️ Stretched (KC2): stop is set a little wider to avoid a whipsaw, so the reward/risk reads a bit lower by design.

· KC2 upper stretch — standard mean-reversion tier
· Counter-trend short in strong uptrend

How this grade was earned

total 22 pts

Cycle position 22

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $282.41 (fair range $37–$282); today's price leaves a +13% cushion below that estimate. The model's verdict is “Undervalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$282.41

Fair-value range

$36.54 – $282.41

Margin of safety

+13%

Verdict

Undervalued

Accounting quality Weak

✓ Gross margin 72% (pricing power)

⚠ Debt exceeds cash
⚠ Quick ratio 0.51 (fragile)
⚠ Current ratio 0.67 (fragile)
⚠ Negative retained earnings

Price implies ~10% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

ABBV is a $449.6 billion company, priced at 125× last year's earnings, and it moves more calmly than the market (beta 0.3); the stock is trading near the top of its 52-week range.

Mkt cap $449.6B

P/E ttm 124.8

Fwd P/E 15.6

Beta 0.28

Day range $254.29 – $260.96

52w range $190.75 – $261.64

Avg vol 7.1M

RSI(2) 88.2

ROE —

Net mgn 5.8%

FCF mgn 33.1%

Debt/Eq —

Div yld 2.72%

Sector Healthcare

Industry Drug Manufacturers - General

Next earn 2026-07-31

52-week range · today's price

$190.75$261.64

More on ABBV

Options idea

See more →

CALL $250 2026-08-21

$12.50

PUT $250 2026-08-21

$7.10

Earnings

See more →

Last reported: 2026-04-29
EPS (act / est): 2.65 / 2.67
Surprise: -0.8%
Next report: 2026-07-31

About

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere…